Active Biotech AB, of Lund, Sweden, said it is planning a rights issue of approximately SEK48 million (US$6 million). When implemented, existing shareholders will be entitled to subscribe for the new shares with preemptive rights, with two existing shares entitling a holder to subscribe for one new share at SEK1 per share.